An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of SPM 927 in Subjects With Chronic Refractory Neuropathic Pain.
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Lacosamide (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors UCB Pharma Inc
- 07 Apr 2011 Status changed from active, no longer recruiting to completedas reported by ClinicalTrials.gov.
- 11 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 12 Oct 2010 Planned end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.